Peptomyc

Barcelona, ES · 2 known investors

Peptomyc develops cell-penetrating mini-protein therapeutics targeting MYC, a central driver of cancer proliferation and treatment resistance, with its lead candidate OMO-103 in clinical trials for multiple cancer types. The company serves cancer patients with MYC-dysregulated tumors across a broad range of cancer indications.